Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies - PubMed (original) (raw)

Affiliations

PMID: 1740756

Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies

M Arendrup et al. J Acquir Immune Defic Syndr (1988). 1992.

Abstract

The capacity of consecutive human sera to neutralize sequentially obtained autologous virus isolates was studied. HIV-1 was isolated three times over a 48-164-week period from three individuals immediately after seroconversion and from two individuals in later stages of infection. Development of neutralizing antibodies to the primary virus isolates was detected 13-45 weeks after seroconversion. Emergence of escape virus with reduced sensitivity to neutralization by autologous sera was demonstrated. The patients subsequently developed neutralizing antibodies against the escape virus but after a delay. Titers of neutralizing antibodies against late virus isolates were generally low compared to initial neutralizing titers against primary virus isolates. The delay in appearance of neutralizing antibodies to the dominant viral strain at any time in the patient and the emergence of neutralization resistant escape virus may be part of the explanation of the apparent failure of the immune system to control HIV infection.

PubMed Disclaimer

Cited by

HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens.
Fischer W, Giorgi EE, Chakraborty S, Nguyen K, Bhattacharya T, Theiler J, Goloboff PA, Yoon H, Abfalterer W, Foley BT, Tegally H, San JE, de Oliveira T; Network for Genomic Surveillance in South Africa (NGS-SA); Gnanakaran S, Korber B. Fischer W, et al. Cell Host Microbe. 2021 Jul 14;29(7):1093-1110. doi: 10.1016/j.chom.2021.05.012. Epub 2021 Jun 3. Cell Host Microbe. 2021. PMID: 34242582 Free PMC article. Review.
Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNAbs or plasma from PLWH.
Tomescu C, Kroll K, Colon K, Papasavvas E, Frank I, Tebas P, Mounzer K, Reeves RK, Montaner LJ. Tomescu C, et al. Eur J Immunol. 2021 Aug;51(8):2051-2061. doi: 10.1002/eji.202149188. Epub 2021 Jun 19. Eur J Immunol. 2021. PMID: 34086344 Free PMC article.
Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes.
Nelson AN, Goswami R, Dennis M, Tu J, Mangan RJ, Saha PT, Cain DW, Curtis AD, Shen X, Shaw GM, Bar K, Hudgens M, Pollara J, De Paris K, Van Rompay KKA, Permar SR. Nelson AN, et al. J Virol. 2019 Jul 17;93(15):e00168-19. doi: 10.1128/JVI.00168-19. Print 2019 Aug 1. J Virol. 2019. PMID: 31092583 Free PMC article.
HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.
van Schooten J, van Gils MJ. van Schooten J, et al. Retrovirology. 2018 Nov 26;15(1):74. doi: 10.1186/s12977-018-0457-7. Retrovirology. 2018. PMID: 30477581 Free PMC article. Review.
Longitudinal Analysis of Cerebrospinal Fluid and Plasma HIV-1 Envelope Sequences Isolated From a Single Donor with HIV Asymptomatic Neurocognitive Impairment.
Vázquez-Santiago F, García Y, Rivera-Román I, Noel RJ Jr, Wojna V, Meléndez LM, Rivera-Amill V. Vázquez-Santiago F, et al. J Virol Antivir Res. 2015;4(1):10.4172/2324-8955.1000135. doi: 10.4172/2324-8955.1000135. J Virol Antivir Res. 2015. PMID: 26167513 Free PMC article.

Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies - PubMed (original) (raw)